Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Publication of CR7162ApublicationCriticalpatent/CR7162A/en
se refiere a una combinacion de un agonista selectivo del receptor A2a de adenosina y un agente anticolinergico para la administracion simultanea, consecutiva o separada por via de inhalacion en el tratamiento de una enfermedad obstructiva de las vias aereas u otra enfermedad inflamatoria, con la condicion de que el agente anticolinergico no sea una sal de tiotropio.refers to a combination of a selective adenosine A2a receptor agonist and an anticholinergic agent for simultaneous, consecutive or separate administration by inhalation in the treatment of an obstructive airway disease or other inflammatory disease, with the condition of that the anticholinergic agent is not a tiotropium salt.
CR7162A2001-05-252003-11-19
AN A2A AGONIST IN COMBINATION WITH AN ANTI-POLINERGIC AGENT FOR THE TREATMENT OF AIRWAY OBSTRUCTIVE DISEASES
CR7162A
(en)
Restless Leg Syndrome Treatment Method, Adenoin a2a Receptor Antagonist Use, Therapeutic Agent for Restless Leg Syndrome, and Night Myoclonus Treatment Method